Analysts forecast that Genocea Biosciences Inc (NASDAQ:GNCA) will report earnings of ($0.14) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Genocea Biosciences’ earnings, with estimates ranging from ($0.15) to ($0.13). Genocea Biosciences reported earnings of ($0.54) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 74.1%. The company is expected to announce its next earnings results on Wednesday, August 8th.
According to Zacks, analysts expect that Genocea Biosciences will report full year earnings of ($0.68) per share for the current financial year, with EPS estimates ranging from ($0.74) to ($0.62). For the next fiscal year, analysts expect that the business will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.86) to ($0.60). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Genocea Biosciences.
Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.14) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.14).
GNCA has been the subject of several recent analyst reports. Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, April 18th. Cantor Fitzgerald began coverage on Genocea Biosciences in a research note on Monday, March 5th. They issued an “overweight” rating and a $5.00 target price for the company. HC Wainwright set a $5.00 target price on Genocea Biosciences and gave the stock a “buy” rating in a research note on Monday, April 30th. Finally, ValuEngine raised Genocea Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $4.41.
Shares of NASDAQ GNCA opened at $0.93 on Wednesday. Genocea Biosciences has a 12 month low of $0.79 and a 12 month high of $6.78. The company has a quick ratio of 8.06, a current ratio of 8.06 and a debt-to-equity ratio of 1.00. The stock has a market cap of $85.70 million, a PE ratio of -0.47 and a beta of 1.20.
A number of institutional investors and hedge funds have recently modified their holdings of the business. BVF Inc. IL purchased a new stake in shares of Genocea Biosciences during the first quarter valued at approximately $5,250,000. Birchview Capital LP boosted its stake in shares of Genocea Biosciences by 384.6% during the first quarter. Birchview Capital LP now owns 189,000 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 150,000 shares during the period. NEA Management Company LLC purchased a new stake in shares of Genocea Biosciences during the first quarter valued at approximately $26,250,000. Millennium Management LLC purchased a new stake in shares of Genocea Biosciences during the fourth quarter valued at approximately $145,000. Finally, BlackRock Inc. boosted its stake in shares of Genocea Biosciences by 169.1% during the first quarter. BlackRock Inc. now owns 3,960,353 shares of the biotechnology company’s stock valued at $4,159,000 after purchasing an additional 2,488,540 shares during the period. 61.94% of the stock is owned by institutional investors and hedge funds.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.